Hi Testy,

Not your bad at all.  It's all good info but sometimes difficult to interpret.  The Italian authors you cited showed that upregulation of FXR inhibited pulmonary fibrosis and inflammation but I found papers by a Chinese group of researchers postulating that upregulation of FXR and TGF-b was associated with increased pulmonary fibrosis.  So, the jury is still out on this one - and perhaps the degree of FXR downregulation that would be achieved by apabetalone would be just right in some lung disease situations.  This is getting a bit esoteric for an RVX investor forum so I won't post the links to the Chinese studies.